UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_________________________________________________________
FORM 8-K
__________________________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 14, 2022
__________________________________________________________
(Exact name of registrant as specified in its charter)
________________________________________________________________
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||
(Address of principal executive offices, including zip code)
(801 ) 708-6800
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
______________________________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
______________________________________________________________
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of exchange on which registered | ||||||||||||
________________________________________________________
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 ((§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07. Submission of Matters to a Vote of Security Holders.
On June 14, 2022, Health Catalyst, Inc. (the “Company”) held its annual meeting of stockholders (the “Annual Meeting”). The Company's stockholders voted on three proposals at the Annual Meeting, each of which is described in greater detail in the Company’s definitive proxy statement filed with the U.S. Securities and Exchange Commission on April 27, 2022. The number of shares of the Company's common stock entitled to vote at the Annual Meeting was 53,937,142. The number of shares of the Company's common stock present or represented by valid proxy at the Annual Meeting was 46,176,662. The final voting results with respect to each such proposal are set forth below.
Proposal 1 – Election of Directors
The Company's stockholders elected each of the two persons named below to serve as a Class III director of the Company to serve a three-year term ending at the 2025 annual meeting or until his successor is elected and qualified. The results of such vote were as follows:
Director Name | Votes For | Votes Withheld | Broker Non-Votes | |||||||||||||||||
| Duncan Gallagher | 28,400,049 | 14,766,137 | 3,010,476 | |||||||||||||||||
| Mark B. Templeton | 33,605,452 | 9,560,734 | 3,010,476 | |||||||||||||||||
Proposal 2 – Ratification of Appointment of Independent Registered Public Accounting Firm
The Company's stockholders ratified the appointment of Ernst & Young LLP to perform the audit of the Company’s consolidated financial statements for the fiscal year ending December 31, 2022. The results of such vote were as follows:
| Votes For | Votes Against | Abstentions | ||||||||||||
| 45,758,062 | 378,823 | 39,777 | ||||||||||||
Proposal 3 – To approve, on an advisory, non-binding basis, the compensation of the Company’s named executive officers
The stockholders did not approve the non-binding, advisory proposal to approve the compensation of the Company’s named executive officers. The results of such vote were as follows:
Votes For | Votes Against | Abstentions | Broker Non-Votes | |||||||||||||||||
| 20,019,370 | 23,100,748 | 46,068 | 3,010,476 | |||||||||||||||||
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| HEALTH CATALYST, INC. | ||||||||
| Date: June 17, 2022 | By: | /s/ Bryan Hunt | ||||||
| Bryan Hunt | ||||||||
| Chief Financial Officer | ||||||||